Broughton announces new US subsidiary and next phase of growth

Broughton is establishing a U.S. subsidiary to enhance its presence in the region.

Broughton, a global Contract Research Organization (CRO) rapidly developing its position as a full-service solutions provider to the global life sciences sector, continues its commitment to helping clients accelerate the delivery of life-enhancing products to market across the pharmaceutical, nicotine and cannabinoid sectors.

With a growing customer base in North America, the business is establishing a US Subsidiary with the aim of building its presence in the region. Leading the US team will be Dr. Tony Jones, who joins Broughton as Managing Consultant. Tony brings a wealth of experience in the field of toxicology and risk assessment, as well as a dedication to excellence in project delivery for clients operating in the pharmaceutical, nicotine, and cannabinoid industries.

With the expansion of Broughton’s services covering product development, scientific and regulatory consultancy, and laboratory services across three industry sectors, the consultancy team has been further strengthened with several key appointments.

Alongside Tony Jones’ appointment, the toxicology team has expanded its desk-based and experimental toxicology capabilities with the additions of Libby Clarke and Dr. Carol Beevers. Both Libby and Carol have worked on multiple regulatory submission projects. Libby is a European Registered Toxicologist (ERT) and has substantial experience devising toxicology testing strategies and compiling submissions to regulatory bodies, including FDA and Health Canada. Carol is a genetic toxicology specialist and has contributed to more than 20 papers in peer-reviewed journals. She is a member of the UK Committee on Mutagenicity and several international working groups on genotoxicity testing.

In recognition of the growing importance of behavioral science in regulatory submissions, Broughton has strengthened its in-house team with the appointment of Oliver Knight-West. Oliver has conducted multiple behavioral and clinical studies into next-generation nicotine products (NGPs) and pharmaceuticals for dossier submission to the FDA, MHRA and EMA regulatory bodies. He has also published many scientific papers in several highly cited publications.

The foundation of the Broughton business is built on excellence in chemistry. To complement the appointment of Paul Hardman in 2021, Malcolm Saxton has joined the chemistry consultancy team. Malcolm will help ensure that Broughton remains at the forefront of the industry in terms of novel method development aligned with evolving market and regulatory needs.

Tony Jones commented: “I am delighted to be spearheading this exciting next stage of the development of Broughton in the US market.

“I’m looking forward to introducing the full lifecycle development services offered by the Broughton team to US clients across pharmaceuticals, nicotine and cannabinoids to help the company support their clients to accelerate innovation to market and improve health outcomes.”    

Chris Allen, CEO, added: ‘’Since 2006, our focus has always been to help our clients succeed. With a passion for enhancing societal health and wellbeing, the establishment of a North American subsidiary is a natural next step to enable us to better partner with our customers in the region.

“The ongoing expansion of our team reflects our continued commitment and ambition to become the most trusted integrated services provider in the world.” For more information contact us here.

Can we help you?

Broughton have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; creating a smoke-free future.

Book a meeting with us today to discuss your requirements.